Business
BioXcel Therapeutics is a biopharmaceutical company using AI to develop neuroscience medicines, with OnkosXcel focused on immuno-oncology.
BioXcel's FY2025 revenue fell 71.7% and losses widened, while debt rose and forensic screens were distress-level.
The read at a glance✓ Audited against SEC data
- Business mix — AI-enabled biopharmaNote
- Revenue — $0.6M, -71.7%Watch
- Net income — -$69.9MWatch
- FCF — -$57.6MWatch
- Debt — $109.6M, +6.9%Watch
- Insiders — 0 purchases / 0 salesNote
- Accounting — Altman distress; Beneish unavailable; EQ distressWatch
Where the revenue comes from
Fiscal 2025, as BioXcel Therapeutics, Inc. reports it. History and quarterly detail are in the app.
- Single Reportable$642K
Leadership changes
From BioXcel Therapeutics, Inc.'s own filings, the day they're filed.
- Rajiv Patni · director · appointmenteff. 2025-01-15
- David Mack · director · appointmenteff. 2024-11-21
- Good Reason · departure
Latest filings
- 8-K · Company announcement2026-09-01
- 8-K · Company announcement2026-08-28
- 8-K · Company announcement2026-08-25
- 8-K · Company announcement2026-08-24
- 10-Q · Quarterly report2026-08-13
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about BioXcel Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.